JP2025509613A - がん治療のためのMetAP2阻害剤を含む組み合わせ - Google Patents
がん治療のためのMetAP2阻害剤を含む組み合わせ Download PDFInfo
- Publication number
- JP2025509613A JP2025509613A JP2024554864A JP2024554864A JP2025509613A JP 2025509613 A JP2025509613 A JP 2025509613A JP 2024554864 A JP2024554864 A JP 2024554864A JP 2024554864 A JP2024554864 A JP 2024554864A JP 2025509613 A JP2025509613 A JP 2025509613A
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- combination
- ceutically acceptable
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320347P | 2022-03-16 | 2022-03-16 | |
| US63/320,347 | 2022-03-16 | ||
| US202263340726P | 2022-05-11 | 2022-05-11 | |
| US63/340,726 | 2022-05-11 | ||
| PCT/US2023/064550 WO2023178255A1 (en) | 2022-03-16 | 2023-03-16 | Combinations comprising metap2 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509613A true JP2025509613A (ja) | 2025-04-11 |
| JP2025509613A5 JP2025509613A5 (https=) | 2026-03-26 |
Family
ID=85979451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554864A Pending JP2025509613A (ja) | 2022-03-16 | 2023-03-16 | がん治療のためのMetAP2阻害剤を含む組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260014194A1 (https=) |
| EP (1) | EP4493181A1 (https=) |
| JP (1) | JP2025509613A (https=) |
| KR (1) | KR20240164549A (https=) |
| CN (1) | CN119300818A (https=) |
| AU (1) | AU2023235307A1 (https=) |
| CA (1) | CA3245962A1 (https=) |
| MX (1) | MX2024011197A (https=) |
| WO (1) | WO2023178255A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102485537B1 (ko) * | 2014-08-04 | 2023-01-05 | 메르크 파텐트 게엠베하 | Metap-2 저해제로서의 피롤리디논 유도체 |
| JP2022512826A (ja) * | 2018-10-26 | 2022-02-07 | シンデブルックス,インコーポレイティド | MetAP2阻害剤のバイオマーカーとその応用 |
-
2023
- 2023-03-16 CA CA3245962A patent/CA3245962A1/en active Pending
- 2023-03-16 US US18/846,365 patent/US20260014194A1/en active Pending
- 2023-03-16 JP JP2024554864A patent/JP2025509613A/ja active Pending
- 2023-03-16 EP EP23716148.4A patent/EP4493181A1/en active Pending
- 2023-03-16 KR KR1020247034327A patent/KR20240164549A/ko active Pending
- 2023-03-16 AU AU2023235307A patent/AU2023235307A1/en active Pending
- 2023-03-16 MX MX2024011197A patent/MX2024011197A/es unknown
- 2023-03-16 WO PCT/US2023/064550 patent/WO2023178255A1/en not_active Ceased
- 2023-03-16 CN CN202380040935.XA patent/CN119300818A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119300818A (zh) | 2025-01-10 |
| US20260014194A1 (en) | 2026-01-15 |
| MX2024011197A (es) | 2024-09-18 |
| AU2023235307A1 (en) | 2024-10-17 |
| WO2023178255A9 (en) | 2024-09-26 |
| EP4493181A1 (en) | 2025-01-22 |
| WO2023178255A1 (en) | 2023-09-21 |
| KR20240164549A (ko) | 2024-11-19 |
| CA3245962A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2269604B1 (en) | Treatment of solid kidney tumours with a rapamycin derivative | |
| EP4385571B1 (en) | A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis | |
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| TW201919615A (zh) | 用於治療tnbc的化合物 | |
| JP2021505571A (ja) | 末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法 | |
| JP2021169534A (ja) | 化学療法の改善 | |
| WO2021180111A1 (zh) | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 | |
| US11083722B2 (en) | Combination therapies for the treatment of breast cancer | |
| JP2024542633A5 (https=) | ||
| JP2024542633A (ja) | がん治療用cdk4阻害剤 | |
| JP2023501912A (ja) | 急性骨髄性白血病の治療のためのdhodh阻害剤を含む組成物 | |
| JP2016520665A (ja) | Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ | |
| Feng et al. | Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions | |
| US11389536B2 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
| US20260014194A1 (en) | Combinations comprising metap2 inhibitors for the treatment of cancer | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| RU2847580C1 (ru) | Терапевтическое средство против рака молочной железы | |
| JP4522261B2 (ja) | ブドウ膜黒色腫の処置 | |
| EP4719405A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer | |
| RU2777519C2 (ru) | Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 | |
| TW202519221A (zh) | Wee1抑制劑及pkmyt1抑制劑之組合 | |
| HK40116611A (zh) | 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 | |
| CN119095599A (zh) | 用于治疗实体肿瘤的双重选择性PI3Kδ和γ抑制剂和/或盐诱导型激酶3抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260313 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260313 |